The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Sequoia trial: Which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?

Dec 12, 2019

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked about the results of the Sequoia trial and which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?

Constantine Tam discusses the results of the trial investigating efficacy and safety of zanubrutinib, a small molecule BTK inhibitor, in patients with 17p deletion CLL, unsuitable for chemotherapy.

Sequoia trial: Which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?